Results 251 to 260 of about 264,861 (313)
Some of the next articles are maybe not open access.
Acute promyelocytic leukemia: Immunophenotype and differential diagnosis by flow cytometry
Cytometry. Part B, Clinical cytometry, 2022Prompt diagnosis of acute promyelocytic leukemia (APL) is critical for patient care. In this study, we aimed to characterize the immunophenotype of APL and explore immunophenotypic difference between APL and its mimics using flow cytometric analysis.
Hong Fang +14 more
semanticscholar +1 more source
American Journal of Hematology, 1979
AbstractAcute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle‐shaped. Electron microscopic appearance of the granules closely resembles that of Auer rods.
J, Groopman, L, Ellman
openaire +2 more sources
AbstractAcute promyelocytic leukemia (APL) is characterized by proliferation of morphologically abnormal promyelocytes and a severe bleeding diathesis. The abnormal promyelocyte is characterized by abundant, large granules, many of which are spindle‐shaped. Electron microscopic appearance of the granules closely resembles that of Auer rods.
J, Groopman, L, Ellman
openaire +2 more sources
Journal of Pediatric Hematology/Oncology, 1995
Significant advances have occurred in the diagnosis, treatment, and long-term outcome of patients with acute promyelocytic leukemia (APL). The purpose of this review is to describe the molecular genetics of this disease, the use of all-trans retinoic acid (ATRA) in clinical trials of APL, and the clinical and basic research questions for future ...
R S, Lemons +6 more
openaire +2 more sources
Significant advances have occurred in the diagnosis, treatment, and long-term outcome of patients with acute promyelocytic leukemia (APL). The purpose of this review is to describe the molecular genetics of this disease, the use of all-trans retinoic acid (ATRA) in clinical trials of APL, and the clinical and basic research questions for future ...
R S, Lemons +6 more
openaire +2 more sources
New England Journal of Medicine, 1993
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Perhaps the most important advance in this field is not the specific actions of all-trans-retinoic acid in acute promyelocytic leukemia, but rather the conclusive documentation of differentiation as a practical and consistently effective method of treating human cancer. As a drug, all-trans-retinoic acid has certain undesirable pharmacologic properties
R P, Warrell +3 more
openaire +2 more sources
Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation
International Journal of Laboratory Hematology, 2020To investigate clinicopathological and molecular features of NPM1‐mutated acute myeloid leukemia that presented with infrequent acute promyelocytic leukemia (APL)‐like phenotype and clinical presentation.
Manuel J Arana Rosainz +8 more
semanticscholar +1 more source
Strategies to inhibit arsenic trioxide‐induced cardiotoxicity in acute promyelocytic leukemia
Journal of Cellular Physiology, 2019Arsenic trioxide (ATO) is a drug commonly used for the treatment of acute promyelocytic leukemia (APL). Although ATO has been shown to cause significant improvement in patients, it is associated with serious side effects, which sometimes lead to the ...
H. Haybar +4 more
semanticscholar +1 more source
Current Treatment Options in Oncology, 2000
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
The treatment of acute promyelocytic leukemia (APL) is different from other subtypes of acute myelocytic leukemia (AML). All trans-retinoic acid (ATRA) is an essential component of the standard remission induction for all newly diagnosed APL patients. Remission induction with ATRA and chemotherapy given concurrently appears to be associated with fewer ...
openaire +2 more sources
Predictors of early hemorrhage in acute promyelocytic leukemia
Leukemia and Lymphoma, 2019Fatal hemorrhage is the most common cause of induction failure and death among patients with acute promyelocytic leukemia (APL). However, there remains no established means of hemorrhagic risk stratification in APL.
L. Naymagon +3 more
semanticscholar +1 more source
Acute Promyelocytic Leukemia: A Summary
Journal of the Advanced Practitioner in Oncology, 2018Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17.
M. Ryan
semanticscholar +1 more source
Best Practice & Research Clinical Haematology, 2014
Acute promyelocytic leukemia (APL) is designated M3 in the French-American-British (FAB) classification. Because of its unique clinical features and unique response to certain differentiation-inducing agents, and because of our advanced understanding of the molecular biology and treatment of this leukemia, APL deserves to be presented and discussed in ...
openaire +1 more source
Acute promyelocytic leukemia (APL) is designated M3 in the French-American-British (FAB) classification. Because of its unique clinical features and unique response to certain differentiation-inducing agents, and because of our advanced understanding of the molecular biology and treatment of this leukemia, APL deserves to be presented and discussed in ...
openaire +1 more source